Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > total addressable market (“TAM”) = 500,000 patients

<< Previous

Bullboard Posts

Next >>

Post by ScienceFirston Mar 09, 2023 5:56pm

322 Views

Post# 35329314

total addressable market (“TAM”) = 500,000 patients

Interesting numbers, from an article on ImmunityBio that targets the same market as us (BCG-Unresponsive):

The highest estimate of BCG efficacy is about 80%, but half of them suffer recurrence as soon as 1 year. Adding in the 20% BCG non-response rate, the total addressable market (“TAM”) for Anktiva is approximately 500,000 individuals for bladder cancer, and this will continue to grow as the rate of people getting the disease is greater than the mortality.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario